SOURCE: TomoTherapy


April 25, 2011 08:00 ET

TomoTherapy Enters Into Radiation Therapy Equipment Purchasing Agreement With ROi

MADISON, WI--(Marketwire - Apr 25, 2011) - TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that it has signed a radiation therapy equipment purchasing agreement with Resource Optimization & Innovation (ROi), one of the healthcare industry's leading supply chain management companies.

"Our agreement with TomoTherapy will provide ROi members with the opportunity to secure one of the most advanced cancer fighting technologies for their patients," said Jim Angelica, senior contract manager at ROi.

Under this five-year contract, TomoTherapy's advanced radiation therapy equipment will be available to ROi's more than 1,400 members, including 35 hospitals and clinics throughout Arkansas, Illinois, Kansas, Missouri and Oklahoma.

"With daily imaging capabilities and precise delivery of radiation, TomoTherapy® treatment systems are bringing numerous proven treatment benefits to cancer patients around the world," said Fred Robertson, TomoTherapy's president and CEO. "We look forward to working with ROi and its members to bring our technology to new communities throughout the Midwestern U.S."

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit

©2011 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoHD, TomoMobile, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

Contact Information

  • Investor Contact:
    Thomas E. Powell
    Chief Financial Officer
    Email Contact

    Media Contacts:
    Kevin O'Malley
    Director, Corporate Communications
    Email Contact

    Susan Lehman
    Rockpoint Public Relations
    Email Contact